Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Presenters

Juan Marín Jiménez

Citation

Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268

Authors

J.A. Marín Jiménez1, A. Capasso2, S.M. Bagby3, S.J. Hartman3, J. Shulman4, J. Barkow4, B.W. Yacob3, P. Blatchford5, T.M. Pitts3, J. Lang4

Author affiliations

  • 1 Department Of Medical Oncology, Catalan Institute of Oncology (Hospital Duran i Reynals), 08908 - Hospitalet de Llobregat/ES
  • 2 Department Of Oncology,, Dell Medical School, University of Texas at Austin, 78712 - Austin/US
  • 3 Division Of Medical Oncology, University of Colorado, Anschutz Medical Campus, 80045 - Aurora/US
  • 4 Immunology And Microbiology, University of Colorado, Anschutz Medical Campus, 80045 - Aurora/US
  • 5 Biostatistics And Informatics, University of Colorado, Anschutz Medical Campus, 80045 - Aurora/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3430

Background

Immune checkpoint inhibition monotherapy has shown no efficacy in microsatellite-stable (MSS) CRC. Combination strategies are being studied to increase the immunogenicity of this cold tumor. Humanized mice are promising models to evaluate immunotherapy combinations and their effects in the engrafted human immune system.

Methods

3 MSS CRC patient-derived xenografts were injected subcutaneously into 68 mice previously humanized through CD34+ cord blood-derived hematopoietic cell transplantation. Mice were allocated into 4 equivalent groups based on human chimerism detected in the blood and subsequently treated with anti-PD-1 therapy and/or multi-tyrosine kinase inhibition. At harvest, flow cytometry immune data from the lymph nodes (LN), the spleen (SP) and tumor-infiltrating lymphocytes (TIL) were analyzed. Mice were classified according to the specific growth rate (SGR, % volume / day) of their tumor/s into R (under median SGR) vs non-R (over median SGR).

Results

50 mice were considered either R (26) or non-R (24). In the peripheral immune organs (LN and SP), the total number of immune cells was similar between R and non-R mice. However, a higher percentage of human and T cells was found in the SP of R mice. Interestingly, the percentage of B cells was higher in the LN and SP of non-R mice. In contrast, in the tumor, an increased number of human cells (mostly T cells) was found in R mice. Notably, CD8+ T cells were significantly higher among TILs. A linear regression analysis was performed, and the number of human and T (CD4+ and CD8+) cells in the tumor significantly decreased (P<.001for all of them) with an increasing tumor SGR.Table: 1904P

Periphery % cellsTumor nº cells / g
LNSPRNon-RP*
RNon-RPRNon-RP
Human cells T cells CD4 CD8 B cells95 78 77 23 1094 76 79 20 16.17 .40 .54 .51 .01638 81 77 23 1023 71 75 24 21.009 .017 .68 .72 .00157648 47794 38094 9210 44322745 18191 14852 3052 555.036 .052 .069 .012 .079
*

T-test on Ln-transformed values

Conclusions

Different immune responses were observed both in the periphery and in the tumor between R and non-R mice. The humanized mouse model appears to be a valid model to evaluate immunotherapy combinations for MSS CRC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

University of Colorado, Anschutz Medical Campus.

Funding

University of Colorado, Anschutz Medical Campus.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.